AngioDynamics, Inc.
ANGOHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeAngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company carries a $628.3M market cap, placing it firmly in the small-cap category. The company operates through Med Tech and Med Device segments.
Market Cap
$628.3M
Beta
0.33
P/E (TTM)
—
P/E (Fwd)
-337.78
EPS (TTM)
$-0.88
EPS (Fwd)
$-0.04
ROE
-20.8%
ROA
-5.1%
Cash
$53.9M
Total Debt
$11.0M
Free CF
$21.8M
52W Change
38.1%
Annual Financials
Cash vs Debt
Where ANGO stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, ANGO finished 32.81% above its 150-day moving average ($12.01) and 31.93% above its 200-day moving average ($12.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANGO overbought or oversold?
At the August 26, 2026 close, ANGO's RSI(14) was 71.8, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $53.9M in cash comfortably exceeding the $11.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $21.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -20.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $338.8M (2023) to $320.2M (2026).
With a beta below 0.7, AngioDynamics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ANGO.